Cannabidiol (CBD) is the most promising phytocannabinoid, owing to its non-psychotropic effects, low toxicity, and high tolerability. There are numerous proposed medical applications of CBD, including pain, epilepsy, nausea, appetite, and cancer care. Investigations into these unmet needs will have potential impacts in the treatment of both veterinary and human diseases. Before pursuing trials to evaluate the activity of CBD in a given condition, definition of chronic pharmacokinetics (the concentrations of CBD in the blood over time) must be performed. This would then allow for the determination of appropriate dosing in future therapeutic trials.
Novel Therapeutics Program
Therapeutic development is often a complex, costly, and risky undertaking. Ethos Discovery in collaboration with the Ethos Compounding Pharmacy have a unique opportunity to de-risk the development and market delivery of specific therapeutics.
The features of drugs that would be best fit this approach are drugs that have an available API in the US, have no veterinary approved products, and would be well suited for a science-based marketing approach (compared to a Direct to consumer approach).